Capabilities

XOMA has proven expertise and a fully integrated product development infrastructure to drive biologic product candidates seamlessly from preclinical through product launch. These capabilities include design and execution of preclinical pharmacology, toxicology, and pharmacokinetic/pharmacodynamic studies, pharmacokinetic modeling, pharmaceutical and process development, small and large-scale cGMP manufacturing, as well as clinical and regulatory capabilities.

Our work has yielded marketed monoclonal antibodies, including RAPTIVA®, which we brought forward through our co-development partnership with Genentech. XOMA also played an important role in the scale-up and manufacturing of RAPTIVA® for preclinical and clinical studies, the completion of toxicology and other preclinical studies, the conduct of clinical Phase I and II studies and the manufacture of the antibody using current good manufacturing practices (cGMPs) for Phase 1, 2 and 3 studies.

Currently, we work with companies such as Novartis, Schering-Plough and Takeda, and our collaborations span a wide range of disease states.